EUVIMEDEUVIMED entdecken
Crossref

Outcomes Following Proton Radiation for Pediatric Meningiomas

Elizabeth Thompson, Daniel J Indelicato iD, Ryan J Brisson, Julie A Bradley, Darren Klawinski, Nathan J Ranalli, Raymond B Mailhot Vega

Pediatric Blood & Cancer · 2026

DOI: 10.1002/1545-5017.70003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2026. Verfasst von Elizabeth Thompson und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of Florida College of Medicine, Jacksonville, Florida, USA. Hauptthemen laut MEDLINE: Meningioma, Proton Therapy, Meningeal Neoplasms, Neoplasm Recurrence, Local. Die Arbeit nennt 9 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pediatric meningiomas make up 2% of all pediatric central nervous system tumors and are distinct from adult meningiomas, often coinciding with neurofibromatosis‐2 (NF2). However, there is limited useful outcome data regarding pediatric meningiomas treated with radiation therapy (RT). Procedures We identified 18 pediatric patients with meningiomas treated at our institution between 2006 and 2024 with proton therapy (PT). All patients received a total dose of 50.4–59.4 Gy in 1.8 Gy/fraction daily, based on tumor grade. Nine patients had WHO Grade I meningiomas and nine had WHO Grade II meningiomas. Sixteen of 18 patients had gross disease at the time of RT. The male‐to‐female ratio was 1:1. Seven of 18 patients had an NF2 diagnosis. Kaplan–Meier statistical analysis was employed to estimate progression‐free survival (PFS), local recurrence, and overall survival (OS) rates. We assessed toxicity during on‐treatment visits and follow‐ups based on severity and need for intervention.

Results

Median follow‐up was 8.5 years (range: 0.5–18 years). No patients were lost to follow‐up. At 10 years, local control was 87%, PFS was 75%, and OS was 94%. One patient died from a radiation‐associated second neoplasm, and one died from cerebral vasculopathy occurring in the high‐dose region. Other notable radiation‐related toxicities included hearing loss ( n = 1), cataract formation ( n = 1), and endocrinopathy ( n = 2). No patients had progressive vision loss.

Conclusion

This study contributes to the limited data for children with meningioma requiring RT. Long‐Term disease control was encouraging and aligned with adult meningioma data. Despite the use of PT, serious radiation toxicity was observed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeningiomaProton TherapyMeningeal NeoplasmsNeoplasm Recurrence, LocalHumansMaleFemaleChildAdolescentChild, PreschoolFollow-Up StudiesSurvival RateRetrospective StudiesInfantPrognosis

Stichwörter der Autor:innen

meningiomapediatricproton therapyradiotherapy

Autor:innen und Institutionen

  • Department of Radiation Oncology, University of Florida College of Medicine, Jacksonville, Florida, USA.
  • Department of Pediatric Hematology/Oncology, Nemours Children's Specialty Clinic, Jacksonville, Florida, USA.
  • Department of Neurosurgery, University of Florida College of Medicine, Jacksonville, Florida, USA.

ORCID-Profile: Daniel J Indelicato

Zitieren

APA

Thompson, E., Indelicato, D. J., Brisson, R. J., Bradley, J. A., Klawinski, D., Ranalli, N. J., & Mailhot Vega, R. B. (2026). Outcomes Following Proton Radiation for Pediatric Meningiomas. Pediatric Blood & Cancer. https://doi.org/10.1002/1545-5017.70003

Vancouver

Thompson E, Indelicato DJ, Brisson RJ, Bradley JA, Klawinski D, Ranalli NJ, et al. Outcomes Following Proton Radiation for Pediatric Meningiomas. Pediatric Blood & Cancer. 2026. doi:10.1002/1545-5017.70003

BibTeX
@article{Thompson2026,
  author = {Thompson, Elizabeth and Indelicato, Daniel J and Brisson, Ryan J and Bradley, Julie A and Klawinski, Darren and Ranalli, Nathan J and Mailhot Vega, Raymond B},
  title = {Outcomes Following Proton Radiation for Pediatric Meningiomas},
  journal = {Pediatric Blood & Cancer},
  year = {2026},
  doi = {10.1002/1545-5017.70003}
}
Kostenlos starten →